IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

Pregnant women with type 1 diabetes who used hybrid closed-loop insulin delivery with Control-IQ technology spent more time ...

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

Children with diabetes who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

CHICAGO -- An investigational allogeneic stem cell-derived islet-cell therapy helped almost all patients with type 1 diabetes ...

Amanda Smith has kicked insulin to the curb in what experts are calling a milestone in the fight against Type 1 diabetes.